Figure 2From: Atopy is a risk factor for respiratory symptoms in COPD patients: results from the EUROSCOP studyMonthly change of FEV 1 from 6 months to 36 months after the start of the study medication. Linear mixed effect models with adjustment for age, BMI, atopy, packyears, and FEV1 % predicted.Back to article page